12.36

0.20% 0.045

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $12.36, with a volume of 2.85M. It is up +0.20% in the last 24 hours and up +16.26% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$12.31

Open:

$12.02

24h Volume:

2.85M

Relative Volume:

0.40

Market Cap:

$4.00B

Revenue:

$79.21M

Net Income/Loss:

$-143.96M

P/E Ratio:

-25.76

EPS:

-0.4796

Net Cash Flow:

$-189.60M

1W Performance:

-3.10%

1M Performance:

+16.26%

6M Performance:

+272.66%

1Y Performance:

+158.60%

1-Day Range:

$11.78

$12.41

1-Week Range:

$11.78

$12.97

52-Week Range:

$2.745

$13.18

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (595)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	12.34	3.99B	79.21M	-143.96M	-189.60M	-0.4796
VRTX Vertex Pharmaceuticals Inc	522.86	130.87B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.74	82.55B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	186.44	72.70B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	957.20	59.17B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	194.84	40.88B	742.00K	-1.37B	-1.07B	-7.0731

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

06:33 AM

Goldman Sachs resumes AbCellera stock coverage with neutral rating By Investing.com - Investing.com Canada

06:33 AM

05:47 AM

ABCL Looks 201.0% Overvalued on GF Value™ - GuruFocus

05:47 AM

Sep 22, 2026